BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 5051257)

  • 21. The depot compounds moditen (fluphenazine) and IMAP (fluspirilene) in clinical practice.
    Faltus F
    Act Nerv Super (Praha); 1974 Aug; 16(3):167-8. PubMed ID: 4607824
    [No Abstract]   [Full Text] [Related]  

  • 22. [Direct treatment of psychotic symptoms with an incisive neuroleptic (Dapotum Acutum)].
    Bermejo E
    Rev Med Suisse Romande; 1976 Dec; 96(12):951-3. PubMed ID: 1006000
    [No Abstract]   [Full Text] [Related]  

  • 23. [Results of treatment by Moditen Depot in outpatients' wards in the South Moravian Region (author's transl)].
    Rektor L; Blazek J
    Cesk Psychiatr; 1980; 76(6):369-75. PubMed ID: 7471277
    [No Abstract]   [Full Text] [Related]  

  • 24. [Experience in the management of chronic psychoses using fluphenazine-oenanthate].
    Eichstetter F
    Nervenarzt; 1968 Jun; 39(6):282-3. PubMed ID: 5712435
    [No Abstract]   [Full Text] [Related]  

  • 25. Flupheazine enenthate and schizophrenia.
    Valentine M; Trueman H
    Br Med J; 1968 Nov; 4(5626):328. PubMed ID: 5687977
    [No Abstract]   [Full Text] [Related]  

  • 26. [Fluphenazine enanthate, delayed-action neuroleptic dru utilizable in outpatients treatment of chronic psychosis].
    Lambert PA; Midenet M; Marcou G; Bouchardy M
    J Med Lyon; 1967 Mar; 48(116):351-5. PubMed ID: 5614941
    [No Abstract]   [Full Text] [Related]  

  • 27. [Treatment with depot neuroleptic drugs in psychiatry].
    Heinrich K
    Evol Psychiatr (Paris); 1970; 35(14):953-5. PubMed ID: 5508726
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment of psychoses with a long-acting neuroleptic agent (fluphenazine decanoate). Clinico-psychopathological study of 53 patients].
    La Mura G; Specchio LM; Corfiati L; Porro V; Bertolino A
    Acta Neurol (Napoli); 1974; 29(4):446-59. PubMed ID: 4615572
    [No Abstract]   [Full Text] [Related]  

  • 29. Controlled trial of depot fluphenazine in out-patient schizophrenics.
    Crawford R; Forrest A
    Br J Psychiatry; 1974 Apr; 124(0):385-91. PubMed ID: 4599422
    [No Abstract]   [Full Text] [Related]  

  • 30. Depot fluphenazine: risk/benefit ratio.
    Glazer WM
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):28-35. PubMed ID: 6370986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical experiences with a delayed-action preparation of fluphenazine].
    Schwingenheuer J
    Arzneimittelforschung; 1972 Nov; 22(11):1918-21. PubMed ID: 4633589
    [No Abstract]   [Full Text] [Related]  

  • 32. [Results of the use of fluphenazine in a depot preparation].
    Marcjan K; Pietruszewska I; Wolak E
    Psychiatr Neurol Med Psychol Beih; 1975; 20-21():176-82. PubMed ID: 829619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical test of noxiptilin in the scope of cooperative testing in 5 psychiatric hospitals].
    Eckmann F; Immich H; Neumann H; Schäpperle O; Schwarz H; Tempel H
    Arzneimittelforschung; 1969 Jun; 19():Suppl 5a:893+. PubMed ID: 4895493
    [No Abstract]   [Full Text] [Related]  

  • 34. Long acting phenothiazines and long term psychotic patients: the role of fluphenazine enanthate in treatment.
    Wintrob RM
    Dis Nerv Syst; 1970 Sep; 31():Suppl:50-62. PubMed ID: 4990944
    [No Abstract]   [Full Text] [Related]  

  • 35. [Clinical study of a hallucinolytic, azacyclonol chlorhydrate (concentrated frenquel: Laboratoire Toraude)].
    Haumonte T; Lefèvre E; Wurtz D
    Ann Med Psychol (Paris); 1968 Nov; 2(4):575-81. PubMed ID: 5709616
    [No Abstract]   [Full Text] [Related]  

  • 36. [Secondary effects of Moditen-Retard].
    Fouks L
    Encephale; 1970; ():Suppl:14-8. PubMed ID: 5458708
    [No Abstract]   [Full Text] [Related]  

  • 37. [Evaluation of fluphenazine use since establishment of a psychiatric section].
    Roger BM
    Ann Med Psychol (Paris); 1972 Apr; 1(4):550-5. PubMed ID: 4342755
    [No Abstract]   [Full Text] [Related]  

  • 38. Spiramycin-associated acute dystonia during neuroleptic treatment.
    Benazzi F
    Can J Psychiatry; 1997 Aug; 42(6):665-6. PubMed ID: 9288434
    [No Abstract]   [Full Text] [Related]  

  • 39. [Delayed action neuroleptic agents].
    Rainaut J
    Evol Psychiatr (Paris); 1970; 35(4):897-955. PubMed ID: 5503625
    [No Abstract]   [Full Text] [Related]  

  • 40. [Study of the delayed-action form of a synthetic antiparkinsonian drug: Akineton].
    Kammerer T; Schweitzer-Bucher E; Jamet P; Royer M
    Ann Med Psychol (Paris); 1972 May; 1(5):688-96. PubMed ID: 5081112
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.